Insider Transactions Reported by 8 Insiders of Cocrystal Pharma, Inc.

Symbol: COCP on Nasdaq
Location: Bothell, WA

Quick Takeaways

COCP - Cocrystal Pharma, Inc. has 8 insiders with reported activity on this page.
Net insider value flow over the last year: +$219,806.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: $219,806; sell value: $0.
Net share flow: +229,000.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Official SEC Source

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to buying over the last 12 months. Net value: +$219,806.

Buys

$219,806

Shares: 229,000

Insiders: 1

Sells

Shares: 0

Insiders: 0

Net

+$219,806

Shares: +229,000

Insiders: 1

Window (months)	Buy shares	Buy $	Sell $	Net $
0-3	70,000	$67,232	$0	+$67,232
3-6	159,000	$152,574	$0	+$152,574
6-9	0	$0	$0	$0
9-12	0	$0	$0	$0

Cocrystal Pharma, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Et al Phillip Frost MD	Director, 10%+ Owner	$2,930,502	+$219,806	+8.1%	Mixed	24 Feb 2026
Fred Hassan	Director	$2,922,384			Mixed	09 Jan 2026
Richard C. Pfenniger Jr.	Director	$94,867			Mixed	09 Jan 2026
James Joseph Martin	Co-CEO and CFO	$71,394			Mixed	09 Jan 2026
Roger D. Kornberg	Director				Mixed	09 Jan 2026
Anthony J. Japour	Director				Mixed	09 Jan 2026
Sam Lee	President and Co-CEO				Mixed	09 Jan 2026
Steven D. Rubin	Director				Mixed	09 Jan 2026

Top shareholders of Cocrystal Pharma, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Et al Phillip Frost MD	13D/G 3/4/5	Phillip Frost, M.D. · Director, 10%+ Owner	18%	2,462,012	$3,078,992	+$1,349,571	28 Oct 2025	13D/G 3/4/5
Fred Hassan	3/4/5	Director	— mixed-class rows	2,118,845 mixed-class rows	$2,922,384	—	09 Jan 2026	3/4/5
VANGUARD GROUP INC	13F	Company	1.9%	263,987	$258,444	—	31 Dec 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.91%	126,028	$123,382	—	31 Dec 2025	13F
Richard C. Pfenniger Jr.	3/4/5	Director	— mixed-class rows	87,810 mixed-class rows	$94,867	—	09 Jan 2026	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.6%	82,499	$80,778	—	31 Dec 2025	13F
BlackRock, Inc.	13F	Company	0.53%	73,746	$72,197	—	31 Dec 2025	13F
James Joseph Martin	3/4/5	Co-CEO and CFO	— mixed-class rows	100,592 mixed-class rows	$71,394	—	09 Jan 2026	3/4/5
T3 Companies, LLC	13F	Company	0.38%	52,300	$51,202	—	31 Dec 2025	13F
DRW Securities, LLC	13F	Company	0.24%	33,593	$32,887	—	31 Dec 2025	13F
Neuberger Berman Group LLC	13F	Company	0.23%	31,886	$31,216	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	0.15%	20,543	$20,112	—	31 Dec 2025	13F
XTX Topco Ltd	13F	Company	0.11%	15,141	$14,823	—	31 Dec 2025	13F
TWO SIGMA SECURITIES, LLC	13F	Company	0.09%	12,752	$12,484	—	31 Dec 2025	13F
Parallel Advisors, LLC	13F	Company	0.09%	12,569	$12,305	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.09%	11,921	$11,671	—	31 Dec 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.08%	10,626	$10,403	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.07%	9,083	$8,892	—	31 Dec 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0.04%	5,098	$4,991	—	31 Dec 2025	13F
Fortitude Family Office, LLC	13F	Company	0.02%	3,219	$3,151	—	31 Dec 2025	13F
UBS Group AG	13F	Company	0.01%	1,777	$1,740	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	0.01%	948	$928	—	31 Dec 2025	13F
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO	13F	Company	0.01%	817	$800	—	31 Dec 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0.01%	788	$772	—	31 Dec 2025	13F
Clean Yield Group	13F	Company	0%	418	$409	—	31 Dec 2025	13F
CITIGROUP INC	13F	Company	0%	390	$382	—	31 Dec 2025	13F
MAI Capital Management	13F	Company	0%	237	$233	—	31 Dec 2025	13F
NVWM, LLC	13F	Company	0%	84	$82	—	31 Dec 2025	13F
SBI Securities Co., Ltd.	13F	Company	0%	33	$32	—	31 Dec 2025	13F
Root Financial Partners, LLC	13F	Company	0%	7	$7	—	31 Dec 2025	13F
Sam Lee	3/4/5	President and Co-CEO	— class O/S missing	49,229	—	—	09 Jan 2026	3/4/5
Roger D. Kornberg	3/4/5	Director	— class O/S missing	24,615	—	—	09 Jan 2026	3/4/5
Anthony J. Japour	3/4/5	Director	— class O/S missing	16,410	—	—	09 Jan 2026	3/4/5
Steven D. Rubin	3/4/5	Director	— class O/S missing	16,410	—	—	09 Jan 2026	3/4/5

Recent Insider Transactions by Companies or Individuals for Cocrystal Pharma, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Et al Phillip Frost MD	COCP	Common Stock	Purchase	1.06%	$19,952	$0.9976	20,000	1,908,551	24 Feb 2026	By Frost Gamma Investments Trust
Et al Phillip Frost MD	COCP	Common Stock	Purchase	2.72%	$47,280	$0.9456	50,000	1,888,551	06 Feb 2026	By Frost Gamma Investments Trust
Roger D. Kornberg	COCP	Stock Options (Right to Buy)	Award				24,615	24,615	09 Jan 2026	Direct
Richard C. Pfenniger Jr.	COCP	Stock Options (Right to Buy)	Award				16,410	16,410	09 Jan 2026	Direct
Sam Lee	COCP	Stock Options (Right to Buy)	Award				49,229	49,229	09 Jan 2026	Direct
Fred Hassan	COCP	Stock Options (Right to Buy)	Award				16,410	16,410	09 Jan 2026	Direct
James Joseph Martin	COCP	Stock Options (Right to Buy)	Award				49,229	49,229	09 Jan 2026	Direct
Et al Phillip Frost MD	COCP	Stock Options (Right to Buy)	Award				24,615	24,615	09 Jan 2026	Direct
Anthony J. Japour	COCP	Stock Options (Right to Buy)	Award				16,410	16,410	09 Jan 2026	Direct
Steven D. Rubin	COCP	Stock Options (Right to Buy)	Award				16,410	16,410	09 Jan 2026	Direct
Et al Phillip Frost MD	COCP	Common Stock	Purchase	2.8%	$47,275	$0.9455	50,000	1,838,551	31 Dec 2025	By Frost Gamma Investments Trust
Et al Phillip Frost MD	COCP	Common Stock	Purchase	1.13%	$19,310	$0.9655	20,000	1,788,551	30 Dec 2025	By Frost Gamma Investments Trust
Et al Phillip Frost MD	COCP	Common Stock	Purchase	2.31%	$38,944	$0.9736	40,000	1,768,551	26 Dec 2025	By Frost Gamma Investments Trust
Et al Phillip Frost MD	COCP	Common Stock	Purchase	1.47%	$24,258	$0.9703	25,000	1,728,551	24 Dec 2025	By Frost Gamma Investments Trust
Et al Phillip Frost MD	COCP	Common Stock	Purchase	0.24%	$3,975	$0.9938	4,000	1,703,551	26 Nov 2025	By Frost Gamma Investments Trust
Et al Phillip Frost MD	COCP	Common Stock	Purchase	1.19%	$18,812	$0.9406	20,000	1,699,551	25 Nov 2025	By Frost Gamma Investments Trust
Et al Phillip Frost MD	COCP	Common Stock	Award	27.2%			359,713	1,679,551	28 Oct 2025	By Frost Gamma Investments Trust
Et al Phillip Frost MD	COCP	Warrants	Award				719,426	719,426	28 Oct 2025	By Frost Gamma Investments Trust
Fred Hassan	COCP	Common Stock	Award	35.2%			359,713	1,383,009	28 Oct 2025	Direct
Fred Hassan	COCP	Warrants	Award				719,426	719,426	28 Oct 2025	Direct
Richard C. Pfenniger Jr.	COCP	Common Stock	Award	175.4%			20,000	31,400	28 Oct 2025	Direct
Richard C. Pfenniger Jr.	COCP	Warrants	Award				40,000	40,000	28 Oct 2025	Direct
James Joseph Martin	COCP	Common Stock	Award	8.87%			3,598	44,167	28 Oct 2025	Direct
James Joseph Martin	COCP	Warrants	Award				7,196	7,196	28 Oct 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.